Mayne Pharma Group Beheer

Beheer criteriumcontroles 1/4

De CEO Mayne Pharma Group is Shawn O’Brien, benoemd in Oct2022, heeft een ambtstermijn van 2.08 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 2.06M, bestaande uit 46.5% salaris en 53.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.075% van de aandelen van het bedrijf, ter waarde A$ 272.66K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 2.7 jaar.

Belangrijke informatie

Shawn O’Brien

Algemeen directeur

AU$2.1m

Totale compensatie

Percentage CEO-salaris	46.5%
Dienstverband CEO	2.1yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	2.7yrs

Recente managementupdates

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

Analyse CEO-vergoeding

Hoe is Shawn O’Brien's beloning veranderd ten opzichte van Mayne Pharma Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$2m	AU$959k	-AU$169m
Mar 31 2024	n/a	n/a	-AU$221m
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

Compensatie versus markt: De totale vergoeding ($USD 1.34M ) Shawn } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 706.54K ).

Compensatie versus inkomsten: De vergoeding van Shawn is gestegen terwijl het bedrijf verliesgevend is.

CEO

Shawn O’Brien (65 yo)

2.1yrs

Tenure

AU$2,062,194

Compensatie

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% A$ 272.7k
Aaron Gray	Chief Financial Officer	2.3yrs	AU$1.31m	0.064% A$ 231.5k
Kimberly Parker	Executive VP & General Counsel	2.8yrs	geen gegevens	geen gegevens
Brant Schofield	Executive Vice President of Corporate Development	3.8yrs	AU$1.29m	geen gegevens
Erinn Nathaniel	Director of Global Human Resources	1.8yrs	geen gegevens	geen gegevens
Daniel Moore	Executive Vice President of Commercial	5.2yrs	geen gegevens	geen gegevens
Frank Casty	Executive VP & Global Chief Medical Officer	1.8yrs	geen gegevens	geen gegevens
Brenton Walter	Financial Controller	20.3yrs	geen gegevens	geen gegevens
Laura Loftus	Associate General Counsel & Company Secretary	4.7yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van MYX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% A$ 272.7k
Frank Condella	Independent Non-Executive Chairman	6.5yrs	AU$305.40k	0.081% A$ 295.4k
Bruce Robinson	Independent Non-Executive Director	10.3yrs	AU$219.39k	0.039% A$ 142.2k
Patrick Blake	Independent Non-Executive Director	6.4yrs	AU$218.36k	0.027% A$ 99.0k
Ann Custin	Independent Non-Executive Director	2.7yrs	AU$235.16k	0.026% A$ 95.7k
Kathryn MacFarlane	Independent Non-Executive Director	2.8yrs	AU$215.84k	0.047% A$ 170.2k
Anne Lockwood	Independent Non Executive Director	less than a year	AU$117.49k	geen gegevens
David Petrie	Non-Executive Director	2.2yrs	AU$217.86k	geen gegevens

2.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MYX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.7 jaar), wat duidt op een nieuw bestuur.

Mayne Pharma Group Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Independent Non-Executive Director recently bought AU$137k worth of stock

Price target decreased to AU$0.42

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published